

			Sale estimates million DKR				
	Royalty	Peak sale	2021	2022	2023	2024	2025
Daratumumab (CD38) MM	17%	10B\$USD	6500	7800	8500	9200	9900
AL Amyloidosis (Dara)							
Non MM blood cancers: phase 2 (Dara)							
Ofatumumab (CD20) MS	10%	2.5B\$USD	250	500	750	1000	1250
Teprotumumab (IGF-1R) Thyroid eye disease	8%	500M\$USD	10	20	30	40	40
Amivantamab	10%	1B\$USD	15	30	60	60	60
Tisotumab Vedotin (Cervical cancer)	50/50	500M\$USD	25	100	150	200	250
Ovarian Cancer	50/50						
Solid tumors	50/50						
Epcoritamab	50/50	5B\$USD	0	1000	2000	4000	8000
HexaBody-CD38							
Total			6800	9450	11490	14500	19500